 The FDA has cleared Tango Therapeutics Incs NASDAQ: TNGX Investigational New Drug IND application for its lead program, TNG908. TNG908 is a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 PRMT5 designed to kill cancer cells with a methylthioadenosine phosphorylase MTAP deletion. 